company background image
1681

Consun Pharmaceutical Group SEHK:1681 Stock Report

Last Price

HK$3.36

Market Cap

HK$2.6b

7D

-0.3%

1Y

-5.1%

Updated

02 Oct, 2022

Data

Company Financials +
1681 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance6/6
Financial Health6/6
Dividends0/6

1681 Stock Overview

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.

Consun Pharmaceutical Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Consun Pharmaceutical Group
Historical stock prices
Current Share PriceHK$3.36
52 Week HighHK$8.00
52 Week LowHK$3.00
Beta0.78
1 Month Change-12.95%
3 Month Change-19.81%
1 Year Change-5.09%
3 Year Change-21.50%
5 Year Change-47.99%
Change since IPO-31.43%

Recent News & Updates

Shareholder Returns

1681HK PharmaceuticalsHK Market
7D-0.3%1.1%-4.4%
1Y-5.1%-37.4%-28.8%

Return vs Industry: 1681 exceeded the Hong Kong Pharmaceuticals industry which returned -37.4% over the past year.

Return vs Market: 1681 exceeded the Hong Kong Market which returned -28.8% over the past year.

Price Volatility

Is 1681's price volatile compared to industry and market?
1681 volatility
1681 Average Weekly Movement6.1%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.4%
10% most volatile stocks in HK Market12.6%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 1681 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 1681's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19973,009Qian Lihttps://www.chinaconsun.com

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography.

Consun Pharmaceutical Group Fundamentals Summary

How do Consun Pharmaceutical Group's earnings and revenue compare to its market cap?
1681 fundamental statistics
Market CapHK$2.65b
Earnings (TTM)HK$702.05m
Revenue (TTM)HK$2.37b

3.8x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1681 income statement (TTM)
RevenueCN¥2.15b
Cost of RevenueCN¥547.48m
Gross ProfitCN¥1.60b
Other ExpensesCN¥967.93m
EarningsCN¥636.26m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.81
Gross Margin74.56%
Net Profit Margin29.57%
Debt/Equity Ratio15.3%

How did 1681 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 1681 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1681?

Other financial metrics that can be useful for relative valuation.

1681 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA0.8x
PEG Ratio0.4x

Price to Earnings Ratio vs Peers

How does 1681's PE Ratio compare to its peers?

1681 PE Ratio vs Peers
The above table shows the PE ratio for 1681 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average5.9x
2877 China Shineway Pharmaceutical Group
5.8x10.8%HK$3.7b
2348 Dawnrays Pharmaceutical (Holdings)
3.9xn/aHK$1.6b
2633 Jacobson Pharma
9.3xn/aHK$1.6b
6600 SciClone Pharmaceuticals (Holdings)
4.5x-2.6%HK$4.2b
1681 Consun Pharmaceutical Group
3.8x9.8%HK$2.6b

Price-To-Earnings vs Peers: 1681 is good value based on its Price-To-Earnings Ratio (3.8x) compared to the peer average (5.9x).


Price to Earnings Ratio vs Industry

How does 1681's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 1681 is good value based on its Price-To-Earnings Ratio (3.8x) compared to the Hong Kong Pharmaceuticals industry average (8.8x)


Price to Earnings Ratio vs Fair Ratio

What is 1681's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1681 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio3.8x
Fair PE Ratio10.7x

Price-To-Earnings vs Fair Ratio: 1681 is good value based on its Price-To-Earnings Ratio (3.8x) compared to the estimated Fair Price-To-Earnings Ratio (10.7x).


Share Price vs Fair Value

What is the Fair Price of 1681 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1681 (HK$3.36) is trading below our estimate of fair value (HK$36.37)

Significantly Below Fair Value: 1681 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Consun Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


9.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1681's forecast earnings growth (9.8% per year) is above the savings rate (1.6%).

Earnings vs Market: 1681's earnings (9.8% per year) are forecast to grow slower than the Hong Kong market (16.8% per year).

High Growth Earnings: 1681's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1681's revenue (10.7% per year) is forecast to grow faster than the Hong Kong market (9.7% per year).

High Growth Revenue: 1681's revenue (10.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1681's Return on Equity is forecast to be high in 3 years time (21.4%)


Discover growth companies

Past Performance

How has Consun Pharmaceutical Group performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


9.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1681 has high quality earnings.

Growing Profit Margin: 1681's current net profit margins (29.6%) are higher than last year (28.9%).


Past Earnings Growth Analysis

Earnings Trend: 1681's earnings have grown by 9% per year over the past 5 years.

Accelerating Growth: 1681's earnings growth over the past year (17.7%) exceeds its 5-year average (9% per year).

Earnings vs Industry: 1681 earnings growth over the past year (17.7%) exceeded the Pharmaceuticals industry 3.7%.


Return on Equity

High ROE: 1681's Return on Equity (20.9%) is considered high.


Discover strong past performing companies

Financial Health

How is Consun Pharmaceutical Group's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 1681's short term assets (CN¥3.1B) exceed its short term liabilities (CN¥1.2B).

Long Term Liabilities: 1681's short term assets (CN¥3.1B) exceed its long term liabilities (CN¥98.3M).


Debt to Equity History and Analysis

Debt Level: 1681 has more cash than its total debt.

Reducing Debt: 1681's debt to equity ratio has reduced from 34.1% to 15.3% over the past 5 years.

Debt Coverage: 1681's debt is well covered by operating cash flow (185.4%).

Interest Coverage: 1681 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Consun Pharmaceutical Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


8.65%

Forecast Dividend Yield

Dividend Yield vs Market

Consun Pharmaceutical Group Dividend Yield vs Market
How does Consun Pharmaceutical Group dividend yield compare to the market?
SegmentDividend Yield
Company (Consun Pharmaceutical Group)0%
Market Bottom 25% (HK)3.0%
Market Top 25% (HK)8.9%
Industry Average (Pharmaceuticals)2.9%
Analyst forecast in 3 Years (Consun Pharmaceutical Group)8.6%

Notable Dividend: Unable to evaluate 1681's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1681's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1681's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1681's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 1681 is not paying a notable dividend for the Hong Kong market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 1681 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Qian Li (57 yo)

9.83yrs

Tenure

CN¥17,752,000

Compensation

Ms. Qian Li has been Vice Chairman at Consun Pharmaceutical Group Limited since November 2020 and serves as its Chief Executive Officer. Ms. Li served as the Chief Executive Officer of Consun Pharmaceutica...


CEO Compensation Analysis

Qian Li's Compensation vs Consun Pharmaceutical Group Earnings
How has Qian Li's remuneration changed compared to Consun Pharmaceutical Group's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

CN¥636m

Mar 31 2022n/an/a

CN¥613m

Dec 31 2021CN¥18mCN¥1m

CN¥590m

Sep 30 2021n/an/a

CN¥565m

Jun 30 2021n/an/a

CN¥541m

Mar 31 2021n/an/a

CN¥520m

Dec 31 2020CN¥14mCN¥1m

CN¥499m

Sep 30 2020n/an/a

CN¥269m

Jun 30 2020n/an/a

CN¥39m

Mar 31 2020n/an/a

CN¥60m

Dec 31 2019CN¥15mCN¥1m

CN¥80m

Sep 30 2019n/an/a

CN¥288m

Jun 30 2019n/an/a

CN¥496m

Mar 31 2019n/an/a

CN¥481m

Dec 31 2018CN¥14mCN¥975k

CN¥465m

Sep 30 2018n/an/a

CN¥448m

Jun 30 2018n/an/a

CN¥430m

Mar 31 2018n/an/a

CN¥413m

Dec 31 2017CN¥12mCN¥973k

CN¥396m

Sep 30 2017n/an/a

CN¥372m

Jun 30 2017n/an/a

CN¥347m

Mar 31 2017n/an/a

CN¥327m

Dec 31 2016CN¥14mCN¥974k

CN¥308m

Sep 30 2016n/an/a

CN¥291m

Jun 30 2016n/an/a

CN¥274m

Mar 31 2016n/an/a

CN¥262m

Dec 31 2015CN¥16mCN¥974k

CN¥250m

Compensation vs Market: Qian's total compensation ($USD2.50M) is above average for companies of similar size in the Hong Kong market ($USD432.34K).

Compensation vs Earnings: Qian's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 1681's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: 1681's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SEHK:1681 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Nov 21BuyHK$2,217,880Qian LiIndividual607,638HK$3.65

Ownership Breakdown

What is the ownership structure of 1681?
Owner TypeNumber of SharesOwnership Percentage
Institutions65,455,1968.3%
General Public254,472,15632.3%
Individual Insiders468,462,35459.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 21 shareholders own 64.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
26.35%
Yubao An
207,737,455CN¥698.0m0%no data
17.27%
Qian Li
136,143,899CN¥457.4m0%no data
13.96%
Wai Po Young
110,050,000CN¥369.8m0%no data
2.75%
The Vanguard Group, Inc.
21,708,521CN¥72.9m5.25%no data
1.84%
Meng An
14,531,000CN¥48.8m0%no data
1.19%
FMR LLC
9,374,938CN¥31.5m0.05%no data
0.74%
BNY Mellon Asset Management
5,856,447CN¥19.7m2.09%no data
0.33%
Jupiter Fund Management Plc
2,618,855CN¥8.8m0%no data
0.13%
State Street Global Advisors, Inc.
1,007,400CN¥3.4m-7.36%no data
0.11%
AXA Investment Managers S.A.
838,000CN¥2.8m0%no data
0.056%
Segall Bryant & Hamill, LLC
445,170CN¥1.5m0%no data
0.037%
Schroder Investment Management Limited
293,728CN¥986.9k0%no data
0.035%
Acadian Asset Management LLC
277,044CN¥930.9k0.02%no data
0.02%
PGIM, Inc.
160,000CN¥537.6k0%no data
0.017%
American Century Investment Management Inc
137,000CN¥460.3k0%no data
0.013%
Fidelity International Ltd
104,000CN¥349.4k0%no data
0.01%
Artico Partners AG
80,000CN¥268.8k0%0.03%
0.008%
FinLABO SIM S.p.A., Asset Management Arm
63,000CN¥211.7k0%0.04%
0.0022%
Legal & General Investment Management Limited
17,000CN¥57.1k0%no data
0.00089%
CCB Principal Asset Management Co., Ltd.
7,000CN¥23.5k0%no data
0.00038%
Connor, Clark & Lunn Investment Management Ltd.
3,000CN¥10.1k0%no data

Company Information

Consun Pharmaceutical Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Consun Pharmaceutical Group Limited
  • Ticker: 1681
  • Exchange: SEHK
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$2.649b
  • Shares outstanding: 788.39m
  • Website: https://www.chinaconsun.com

Number of Employees


Location

  • Consun Pharmaceutical Group Limited
  • 71, Dongpeng Avenue
  • Eastern section
  • Guangzhou
  • Guangdong Province
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1681SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDDec 2013
C1PDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2013

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.